Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Johnson and Johnson
Healthtrust
Express Scripts
AstraZeneca
Harvard Business School
Queensland Health
Federal Trade Commission

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021656

« Back to Dashboard

NDA 021656 describes TRICOR, which is a drug marketed by Abbvie and Abbvie Inc and is included in three NDAs. It is available from thirteen suppliers. There are nine patents protecting this drug and two Paragraph IV challenges. Additional details are available on the TRICOR profile page.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Summary for 021656
Tradename:TRICOR
Applicant:Abbvie
Ingredient:fenofibrate
Patents:7
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021656
Medical Subject Heading (MeSH) Categories for 021656
Suppliers and Packaging for NDA: 021656
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRICOR fenofibrate TABLET;ORAL 021656 NDA AbbVie Inc. 0074-3173 N 0074-3173-90
TRICOR fenofibrate TABLET;ORAL 021656 NDA AbbVie Inc. 0074-3189 N 0074-3189-90

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength48MG
Approval Date:Nov 5, 2004TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 9, 2018Product Flag?Substance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Sep 21, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
Patent:➤ Sign UpPatent Expiration:Jan 9, 2018Product Flag?Substance Flag?YDelist Request?

Expired US Patents for NDA 021656

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ➤ Sign Up ➤ Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 ➤ Sign Up ➤ Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ➤ Sign Up ➤ Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
US Department of Justice
QuintilesIMS
Medtronic
Teva
Argus Health
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.